Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research

摘要: Free to read Introduction Quality glucose information is a core prerequisite for successful diabetes management. It enables professionals and people with make medically relevant decisions on therapy. Details of profile beyond HbA1c have been largely derived from self-monitoring blood (SMBG). Given the evidence base demonstrating benefits SMBG, its routine use recommended management therapy by many international regional guidelines (1–3). Today, SMBG considered an important aspect glycemic control (3,4). Glucose high quality, considering products used processes conducted, also needed in clinical research order gain new insights effective treatment strategies diabetes. widely routinely applied large trials, where it understand state, enhance awareness effects lifestyle modification adaptation including insulin titration, enable documentation intraday pre- postprandial excursions (glycemic variability) subsequent statistical analysis this confirmation hypoglycemic episodes. Examples recent studies that are Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial, Action Control Cardiovascular Risk Diabetes (ACCORD), and, earlier times, Complications Trial (DCCT) (5–8). Indeed, now most glucose-lowering agents, glucagon-like peptide 1 (GLP-1) receptor agonist sodium–glucose cotransporter 2 (SGLT2) inhibitor studies.